Regulation 2013/1259 - Amendment of Council Regulation (EC) No 111/2005 laying down rules for the monitoring of trade between the EC and third countries in drug precursors - Main contents
Please note
This page contains a limited version of this dossier in the EU Monitor.
Contents
official title
Regulation (EU) No 1259/2013 of the European Parliament and of the Council of 20 November 2013 amending Council Regulation (EC) No 111/2005 laying down rules for the monitoring of trade between the Community and third countries in drug precursors| Legal instrument | Regulation |
|---|---|
| Number legal act | Regulation 2013/1259 |
| Original proposal | COM(2012)521  |
| CELEX number i | 32013R1259 |
| Document | 20-11-2013 |
|---|---|
| Publication in Official Journal | 10-12-2013; OJ L 330 p. 30-38 |
| Effect | 30-12-2013; Entry into force Date pub. +20 See Art 2 |
| End of validity | 31-12-9999 |
10.12.2013 |
EN |
Official Journal of the European Union |
L 330/30 |
REGULATION (EU) No 1259/2013 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL
of 20 November 2013
amending Council Regulation (EC) No 111/2005 laying down rules for the monitoring of trade between the Community and third countries in drug precursors
THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION,
Having regard to the Treaty on the Functioning of the European Union, and in particular Article 207(2) thereof,
Having regard to the proposal from the European Commission,
After transmission of the draft legislative act to the national parliaments,
Acting in accordance with the ordinary legislative procedure (1),
Whereas:
(1) |
On 7 January 2010, the Commission adopted a report, pursuant to Article 32 of Council Regulation (EC) No 111/2005 (2), on the implementation and functioning of the Community legislation on monitoring and control of trade in drug precursors. |
(2) |
Trade in medicinal products is not controlled in the existing Union control system for drug precursors, since they are currently excluded from the definition of scheduled substances. |
(3) |
The Commission report pointed out that medicinal products containing ephedrine and pseudoephedrine were diverted into the illicit drug manufacture outside the Union, as a substitute for internationally controlled ephedrine and pseudoephedrine. The Commission therefore recommended strengthening the control of international trade in medicinal products containing ephedrine or pseudoephedrine exported from or transiting through the customs territory of the Union in order to prevent their diversion for the illicit manufacture of narcotic drugs or psychotropic substances. |
(4) |
In its Conclusions of 25 May 2010 on the functioning and implementation of EU drug precursors legislation, the Council invited the Commission to propose legislative amendments after carefully assessing their potential impact on Member States’ authorities and economic operators. |
(5) |
This Regulation clarifies the definition of a scheduled substance: in this regard, the term ‘pharmaceutical preparation’, which stems from the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances adopted in Vienna on 19 December 1988 (‘the United Nations Convention’), is deleted as it is already covered by the relevant terminology of Union legal acts, namely ‘medicinal products’. Moreover, the term ‘other preparations’ is deleted as it duplicates the term ‘mixtures’ already used in that definition. |
(6) |
Rules on suspending or revoking the registration of an operator should be introduced in order to match the existing rules for suspending or revoking a licence. |
(7) |
Medicinal products and veterinary medicinal products (‘medicinal products’) containing ephedrine or pseudoephedrine should be controlled without impeding their legitimate trade. To that end, a new category (Category 4) should be added to the Annex to Regulation (EC) No 111/2005 listing medicinal products containing certain scheduled substances. |
(8) |
The export of medicinal products listed in Category 4 of the Annex to Regulation (EC) No 111/2005, as amended by this Regulation, should be preceded by an export authorisation, and a pre-export notification sent by the competent authorities in the Union to the competent authorities of the country of destination. |
(9) |
Member States’ competent authorities should be given the powers to stop or seize those medicinal products where there are reasonable grounds for suspecting that they are intended for the illicit manufacture of narcotic drugs or psychotropic substances, when they are exported, imported or in transit. |
(10) |
With a view to... |
More
This text has been adopted from EUR-Lex.
This dossier is compiled each night drawing from aforementioned sources through automated processes. We have invested a great deal in optimising the programming underlying these processes. However, we cannot guarantee the sources we draw our information from nor the resulting dossier are without fault.
This page is also available in a full version containing the summary of legislation, the legal context, de Europese rechtsgrond, other dossiers related to the dossier at hand and finally the related cases of the European Court of Justice.
The full version is available for registered users of the EU Monitor by ANP and PDC Informatie Architectuur.
The EU Monitor enables its users to keep track of the European process of lawmaking, focusing on the relevant dossiers. It automatically signals developments in your chosen topics of interest. Apologies to unregistered users, we can no longer add new users.This service will discontinue in the near future.